Targeted Sequencing And Resequencing Market Size, Share & Trends Analysis Report By Technology (NGS, Others), By Workflow, By Application, By Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Targeted Sequencing And Resequencing Market Size, Share & Trends Analysis Report By Technology (NGS, Others), By Workflow, By Application, By Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Targeted Sequencing And Resequencing Market Growth & Trends

The global targeted sequencing and resequencing market size is expected to reach USD 25.7 billion expanding at a CAGR of 22.59% from 2023 to 2030, according to a new report by Grand View Research, Inc. Owing to the continuous technological developments in genome sequencers along with broad applications and adoption of NGS technology is expected drive the market growth. Furthermore, the increasing application of NGS in molecular diagnostics and precision medicione is also anticipated to create growth opportunities for market growth.

NGS is expected to witness increasing adoption in various disease conditions and infectious disease treatment, along with Noninvasive Prenatal Testing, transplant medicine, and pharmacogenomics. Targeted gene panels and gene expression profiling through qPCR remain the two most common applications for NGS sequencers in a pathology laboratory. While oncology remains a primary area of NGS use in clinics, pathologists are expected to adopt it in other areas too over the coming years. Such factors are expected to boost market growth in the forecast period.

On the other hand, the introduction of novel products is expected to boost targeted sequencing and resequencing market growth. For instance, in October 2022, the Illumina genomics Forum introduced the NovaSeq X, which can run around 20,000 whole genomes a year on one system. This novel system has 10 billion flow cells. When run at 2×150 base pair reads, it will output 6 TB. Moreover, in December 2021, F. Hoffmann-La Roche AG launched the AVENIO Edge System for simplifying the automation of NGS sample preparation and driving advancements in precision medicine. This novel system is a pre-analytical platform that offers end-to-end, integrated, consistently high-quality outcomes.

Key entities in the targeted sequencing & resequencing market are focusing on collaboration to strengthen their market position. For instance, in March 2021, Illumina collaborated with Geneseeq to commercialize and develop IVD NGS kits in China for cancer care. This novel kit was developed by using Illumina’s NextSeq 550Dx sequencing system, which was approved by China’s NMPA (National Medical Products Administration). Moreover, in March 2021, Hackensack Meridian Health and Genomic Testing Cooperative (GTC) entered into a partnership to establish an oncology-focused RNA and DNA sequencing laboratory in the U.S. This lab—Anthology Diagnostics—will perform NGS of cell-free DNA from liquid biopsy samples and DNA/RNA from tumor samples.

Targeted Sequencing And Resequencing Market Report Highlights

• The growth of the overall targeted sequencing and resequencing market is attributed to the increase in the adoption of NGS for various applications including disease diagnosis, drug development, and research applications
• By sequencing technology, sequencing segment dominated the market owing to the increase in applications of genome sequencing in human genetic research, microbial research, cancer research, and others
• Clinical application segment held a major share in 2022. Targeted sequencing has broadly applied in clinical research and trials for patient categorization and the development of targeted therapeutics
• Drug development segment is expected to show significant market share in the coming years. NGS technology can develop multiple levels of genomic data needed for the drug development process from genetic modification, to transcriptome quantification and profiling, and epigenetic modifications, among others
• By end-use, Hospitals and clinics is expected show a significant market share in the forecast period. This is attributed to the increasing usage of NGS bu clinicians to test several genes for mutations, copy number changes, and fusions
• North America dominated the targeted sequencing and resequencing market in 2022 due to the presence of key players and favorable government initiatives from the government for increased adoption of NGS technologies